Contents

SPECIAL SECTION ON THERAPEUTIC IMPLICATIONS FOR SPHINGOLIPIDS IN HEALTH AND DISEASE

Special Section on Therapeutic Implications for Sphingolipids in Health and Disease—Editorial
Christopher J. Clarke and Ashley J. Snider

Perspective: Therapeutic Implications for Sphingolipids in Health and Disease
Christopher J. Clarke and Ashley J. Snider

Development of an LC-MS/MS Method to Measure Sphingolipids in CSF from Patients with Multiple Sclerosis

Expression of Ceramide Synthases in Mice and Their Roles in Regulating Acyl-Chain Sphingolipids: A Framework for Baseline Levels and Future Implications in Aging and Disease
Whitney J. Richardson, Sophia B. Humphrey, Sophia M. Sears, Nicholas A. Hoffman, Andrew J. Orwick, Mark A. Doll, Chelsea L. Doll, Catherine Xia, Maria Hernandez-Corbachó, Justin M. Snider, Lisa M. Obeid, Yusuf A. Hannun, Ashley J. Snider, and Leah J. Siskind

A Brief Overview of the Toxic Sphingomyelinase Ds of Brown Recluse Spider Venom and Other Organisms and Simple Methods To Detect Production of Its Signature Cyclic Ceramide Phosphate
Hannah Lachmayr and Alfred H. Merrill, Jr.

Fanning the Flames of Endoplasmic Reticulum (ER) Stress: Can Sphingolipid Metabolism Be Targeted to Enhance ER Stress–Associated Immuno- genic Cell Death in Cancer?
Jeremy A. Hengst, Asvelt J. Nduwumwami, Arati Sharma, and Jong K. Yun

Drug Targeting of Acyltransferases in the Triacylglyceride and 1-O-AcylCeramide Biosynthetic Pathways
Maria Hernandez-Corbachó and Daniel Canals

MINIREVIEW

Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism
Zhenning Yang, Helmut Zarbl, and Grace L. Guo

ARTICLES

ent-Verticilide B1 Inhibits Type 2 Ryanodine Receptor Channels and is Antiarrhythmic in Casq2−/− Mice
Aaron Gochman, Tri Q. Do, Kyungsoo Kim, Jacob A. Schwarz, Madelaine P. Thorpe, Daniel J. Blackwell, Paxton A. Ritschel, Abigail N. Smith, Robyn T. Rebbeck, Wendell S. Akers, Razvan L. Cornea, Derek R. Laver, Jeffrey N. Johnston, and Björn C. Knollmann

Discovery and Characterization of VU0542270, the First Selective Inhibitor of Vascular Kir6.1/SUR2B K+ Channels
Kangjun Li, Samantha J. McClanahan, Changho Han, Joseph D. Bungard, Upendra Rathnayake, Olivier Boutaud, Joshua A. Bauer, Emily L. Days, Craig W. Lindsley, Elaine L. Shelton, and Jerod S. Denton

Supplemental material is available online at molpharm.aspetjournals.org.

About the cover: Cellular sphingolipid biosynthesis and breakdown. See the article by Hengst et al. (dx.doi.org/10.1124/molpharm.123.000786).
Extrahelical Binding Site for a 1H-Imidazo[4,5-c]quinolin-4-amine A3 Adenosine Receptor Positive Allosteric Modulator on Helix 8 and Distal Portions of Transmembrane Domains 1 and 7

Inhibition of Cardiac Kv4.3/KChIP2 Channels by Sulfonylurea Drug Gliquidone
Chenxia Yang, Qinqin Li, Fang Hu, Yani Liu, and KeWei Wang

Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel Na\textsubscript{v}1.8 with a Unique Mechanism of Action
John M. Gilchrist, Nien-Du Yang, Victoria Jiang, and Bryan D. Moyer

Coexpressed δ-, μ-, and κ-Opioid Receptors Modulate Voltage-Gated Ca\textsuperscript{2+} Channels in Gastric-Projecting Vagal Afferent Neurons
Hannah J. Goudsward, Victor Ruiz-Velasco, Salvatore L. Stella, Lisa B. Willing, and Gregory M. Holmes

Nanobody-Mediated Dualsteric Engagement of the Angiotensin Receptor Broadens Biased Ligand Pharmacology
Nayara Braga Emidio, Brandi M. Small, Amanda R. Keller, Ross W. Cheloha, and Laura M. Wingler